Mounjaro is a prescription medicine available as a pre-filled single-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection. For more information, call 1-833-807-MJRO (833-807-6576) or go to www.mounjaro.lilly.com.

Mounjaro® (tirzepatide) is a once-weekly non-insulin injection for adults to help lower A1C along with diet and exercise. Learn how Mounjaro® works and how to get started.

Take the next step in your care journey with LillyDirect® for select Lilly medicines, independent virtual and in-person services, and online pharmacy solutions.

Mounjaro is a once-weekly injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It should be used along with diet and exercise.

Mounjaro® comes in a single-use auto-injection pen; available in 6 doses. Learn how to get your patient started with the appropriate dosage & storage and disposal information.

Mounjaro (tirzepatide) 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL injection, is a prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose). It is not known if Mounjaro can be …

Learn how to use the once-weekly Mounjaro® pen from dosing to storage and disposal. Additionally, find possible side effects that can be associated with Mounjaro®.

MOUNJARO® is a glucose -dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic

INDIANAPOLIS, May 13, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve ...

MOUNJARO is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It is not known if MOUNJARO can be used in people who have had pancreatitis.

1 day ago · Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound …

How does Mounjaro® (tirzepatide) work to improve glycemic control in adults with type 2 diabetes? Tirzepatide improves glycemic control by enhancing insulin secretion, increasing insulin sensitivity, reducing glucagon levels, delaying gastric emptying, and decreasing food intake.

INDIANAPOLIS, June 6, 2022 /PRNewswire/ -- New data from a mechanism of action study and new analyses of the global registration program for Eli Lilly and Company's (NYSE: LLY) Mounjaro™ (tirzepatide) injection were presented at the American Diabetes Association's ® (ADA) 82 nd Scientific Sessions ®, adding to the robust body of data about ...

1 day ago · Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines. On Thursday, Eli Lilly and Co (NYSE:LLY) stock is trading higher after ...

MOUNJARO and MOUNJARO KwikPen (tirzepatide injection) Page 4 of 61 PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS MOUNJARO (tirzepatide injection) is indicated for once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus.

Jan 25, 2025 · While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (LLY-1.48%) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound.

Nov 8, 2023 · Eli Lilly says tirzepatide, a drug used to treat type 2 diabetes, also leads to substantial weight loss in diabetes patients. The drug, called Mounjaro for diabetes, will be called Zepbound for...

1 day ago · Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

Sep 14, 2022 · Lilly's diabetes newcomer Mounjaro is off to a strong start with it's U.S. launch. After snaring approval in May, Eli Lilly’s closely watched diabetes med tirzepatide—now christened

Mounjaro (tirzepatide), an injectable prescription medicine, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Mounjaro has not been studied in patients with a history of pancreatitis. Mounjaro is not indicated for use in patients with type 1 diabetes mellitus.

Mounjaro® (tirzepatide) is the first and only, once-weekly approved single molecule GIP and GLP-1 receptor agonist that helps lower A1C for adults with type 2 diabetes.

Nov 2, 2023 · Supply problems for Eli Lilly’s diabetes med Mounjaro were no secret. But strong demand continues to push sales of the GLP-1/GIP agonist to new highs ahead of an FDA decision on weight loss....

Aug 8, 2023 · Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.

1 day ago · Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

1 day ago · Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and ...